The earnings call presented a balanced view with significant revenue growth and operational expansion countered by increased net losses and rising expenses. Reimbursement improvements and strategic advancements in clinical trials provide a positive outlook, but the challenges in sales force productivity and increased expenses contribute to a cautious sentiment.

Company Guidance -

Q3 2025

During the CVRx Q2 2025 earnings call, the company provided updated financial guidance and discussed key metrics for the quarter. CVRx reported total revenue of $13.6 million, a 15% increase compared to the same quarter in the previous year, with U.S. Heart Failure revenue accounting for $12.2 million. The company expanded to 240 active implanting centers in the U.S., up from 227 in Q1 2025, and increased its U.S. sales territories to 47. Despite ongoing sales force transformation, with over 35% of territory managers hired since January, CVRx remains optimistic about future growth. The company narrowed its full-year 2025 revenue guidance to between $55 million and $57 million, maintaining a gross margin expectation of 83% to 84%. Additionally, CVRx highlighted advancements in its reimbursement strategy, including CMS's proposal to maintain the Barostim implant procedure's assignment to new technology APC 1580 with approximately $45,000 payment for outpatient procedures and the transition to Category 1 CPT codes in January 2026.

Revenue Growth

Total revenue for Q2 2025 was $13.6 million, marking a 15% increase over the same quarter last year.

Expansion of U.S. Operations

The number of active implanting centers in the U.S. increased from 227 to 240, and the number of sales territories expanded from 45 to 47.

Reimbursement Improvements

CMS proposed maintaining Barostim's procedure assignment to a new technology APC with approximately $45,000 payment. Transition to Category 1 CPT codes in 2026 will improve reimbursement predictability.

Clinical Strategy Advancements

Progress in discussions with FDA on a randomized controlled trial design and ongoing development of additional clinical evidence through various trials.

Gross Margin Consistency

Gross margin remained consistent at 84% compared to the prior year period.

Leadership Appointment

Brent Binkowski appointed as Chief Operating Officer, bringing over 20 years of leadership experience in medical devices.

CVRx (CVRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CVRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	-0.50 / -	-0.57	―	―	―
Aug 04, 2025	2025 (Q2)	-0.52 / -0.57	-0.65	12.31% (+0.08)	―
May 08, 2025	2025 (Q1)	-0.57 / -0.53	-1.04	49.04% (+0.51)	―
Feb 04, 2025	2024 (Q4)	-0.38 / -0.43	-0.44	2.27% (+0.01)	―
Oct 29, 2024	2024 (Q3)	-0.50 / -0.57	-0.43	-32.56% (-0.14)	―
Jul 29, 2024	2024 (Q2)	-0.55 / -0.65	-0.56	-16.07% (-0.09)	―
Apr 30, 2024	2024 (Q1)	-0.54 / -1.04	-0.55	-89.09% (-0.49)	―
Jan 25, 2024	2023 (Q4)	-0.54 / -0.44	-0.51	13.73% (+0.07)	―
Oct 26, 2023	2023 (Q3)	-0.58 / -0.43	-0.48	10.42% (+0.05)	―
Jul 25, 2023	2023 (Q2)	-0.58 / -0.56	-0.54	-3.70% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CVRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$7.55	$6.80	-9.93%
May 08, 2025	$7.78	$4.77	-38.69%
Feb 04, 2025	$16.25	$15.08	-7.20%
Oct 29, 2024	$10.74	$14.07	+31.01%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does CVRx (CVRX) report earnings?

CVRx (CVRX) is schdueled to report earning on Nov 04, 2025, After Close (Confirmed).

What is CVRx (CVRX) earnings time?

CVRx (CVRX) earnings time is at Nov 04, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CVRX EPS forecast?

CVRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.5.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing